PRNewswire - April 3, 2003

CV-N is a novel protein isolated from the cyanobacterium, Nostoc ellipsosporum (blue-green algae). Promising results of NIH research into the protein's use in preventing HIV included a primate model in which CV-N was shown to prevent transmission of simian-human immunodeficiency virus (SHIV), an HIV-like virus that infects monkeys. "CV-N is a member of an exciting new class of HIV drugs termed fusion inhibitors," stated Dr. Richard Bax, Vice President and Chief Scientific Officer of Biosyn. "By preventing HIV entry into and fusion with target cells, CV-N effectively inhibits the virus' mode of infection. As an intravaginal gel applied prior to intercourse, CV-N could help to avert the sexual transmission of HIV."

Under the NIH license, Biosyn receives exclusive, worldwide rights to the development and commercialization of CV-N as a microbicide, in exchange for certain milestone and royalty payments to be made to the NIH. "This agreement with NIH greatly expands our portfolio of products in the area of HIV and sexually transmitted disease, an area in which Biosyn commands a leadership position," stated Anne-Marie Corner, President & CEO of Biosyn. As announced in November 2002, the NIH awarded the company a $10 million grant for the development of CV-N as a microbicide. These funds support an ongoing development program for CV-N at Biosyn and will continue to be utilized to progress the drug into clinical trials.

About Microbicides

Microbicides are a novel group of products that, with non-systemic application, have the potential to prevent the spread of sexually transmitted disease (STD) pathogens including HIV, chlamydia, herpes simplex virus, gonorrhea, etc. Microbicides can be produced in several forms including intravaginal gels, creams, and delivery systems that release the active product over time.

About Biosyn

Biosyn is a specialty pharmaceutical company focused on the development and commercialization of novel drugs in the areas of infectious disease and reproductive health. Biosyn's product portfolio offers significant competitive advantages in areas where there is a critical need for new or alternative therapies. The company is developing several products for the prevention of STDs including HIV, chlamydia, gonorrhea and genital herpes.

Biosyn's lead product candidate, 1.0% C31G vaginal gel (Savvy(R)) is entering Phase III clinical trials in 2003 for contraception and the prevention of transmission of STDs. In addition, Biosyn is developing products in other key market segments including oral infections associated with immune-suppression and skin and soft tissue infections (SSTIs).

SOURCE Biosyn, Inc.

Web Site: http://www.biosyn-inc.com

030403
PR030410

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .